Rentschler Biopharma announced this week that it is searching for a new CEO as its current leader Dr. Frank Mathias will return to the company’s supervisory board.
Mathias, who has led Rentschler since April 2016, will return to the board at the end of the company’s fiscal year in March 2023. Still, he will be responsible for overseeing the business operations for the contract development and manufacturing organization for biopharmaceuticals until a successor is appointed.
During his time at the helm, Mathias led the company through a prosperous period as part of its “Growth 2025” initiative. Additionally, Rentschler acquired a U.S. manufacturing site in 2019 and established a U.K. site dedicated to cell and gene therapy as well.
Mathias said in a statement that the company set high goals and achieved those expectations due to “innovation and commitment” from Rentschler’s workforce.
“With our highly experienced management team bringing a wide range of expertise and competences, the course for further success has been set,” Mathias said. “As Rentschler Biopharma enters its next phase of integration and builds on its achievements, it is important for me to continue to support this phase by rejoining the Supervisory Board. I will remain closely associated with the company and look forward to continuing to work with everyone during this transition period and subsequently as a member of the Supervisory Board, to whom I would like to express my sincere thanks for the trust placed in me.”
This is the latest personnel move for Rentschler, which appointed Mark Caswell as VP, site head for its U.S. facility in August.
